Kymera Therapeutics, Inc. (KYMR) Dividend History

Kymera Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degradation therapies to treat serious diseases. Using its proprietary Pegasus platform, the company designs small molecules to selectively degrade disease-causing proteins, aiming to address previously "undruggable" targets in areas such as inflammation, oncology, and genetic disorders. Founded to leverage novel approaches in drug discovery, Kymera aims to transform medicine through innovative targeted degradation strategies.

500 North Beacon Street, 4th Floor, Watertown, MA, 02472
Phone: 857-285-5314
Website: https://www.kymeratx.com

Dividend History

Kymera Therapeutics, Inc. currently does not pay dividends

Company News

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics announced positive results from a Phase 1 trial of its oral STAT6 degrader KT-621, which demonstrated robust STAT6 degradation, favorable Th2 biomarker profile, and a well-tolerated safety profile in healthy volunteers. The company plans to advance KT-621 into Phase 1b and Phase 2b trials for atopic dermatitis and asthma.

GlobeNewswire Inc.
Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics announced positive preclinical data for its oral STAT6 degrader KT-621, which demonstrated superior activity to dupilumab in a chronic asthma model. The company also expanded its immunology pipeline with a new first-in-class, oral IRF5 degrader program.

GlobeNewswire Inc.
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

Kymera Therapeutics reported progress across its pipeline, including the completion of a Phase 1 trial for its STAT6 degrader KT-621 and the initiation of a Phase 1b trial in atopic dermatitis. The company also introduced a new oral immunology program targeting IRF5 and made a strategic decision not to advance its TYK2 degrader KT-295 further.

GlobeNewswire Inc.
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

Kymera Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on May 14, 2025.

GlobeNewswire Inc.
Why Kymera Therapeutics Stock Crushed it This Week

Kymera Therapeutics, a clinical-stage biotech company, saw its stock price gain nearly 23% this week after announcing the initiation of a phase 1b clinical trial for its investigational drug KT-621 to treat eczema, and plans to unveil a new oral immunology program.

The Motley Fool

Dividend data last updated 06/08/2025 00:11:52 UTC